Clinical Trial Update: Study to Evaluate Immunogenicity and Safety of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine at 9 and 10 Years After Vaccine Administration and Assessment of Re-vaccination With 2 Additional Doses at 10 Years After Initial Vaccination, in Healthy Subjects Aged 60 Years of Age(YOA) and Older [Phase 3]

View source ↗

Summary

A Phase 3 trial assessing long-term immunogenicity and safety of GSK's herpes zoster subunit vaccine with re-vaccination at 10 years; results completed with res…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Herpes Zoster

Drugs mentioned

• HZ/su vaccine (genuine vaccine name not provided)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Herpes Zoster | Phase 3 | Status: COMPLETED | Results posted: 2019-11-01